奎奴普丁-达福普汀（Synercid）与利福平联合使用，在实验性金黄色葡萄球菌人工关节感染中具有高度协同作用。
Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
作者信息
Saleh-Mghir Azzam, Ameur Nourdine, Muller-Serieys Claudette, Ismael Farid, Lemaitre Françoise, Massias Laurent, Feger Céline, Bléton Rémy, Crémieux Anne-Claude
机构信息
INSERM EMI-U 9933, Hôpital Bichat-Claude Bernard, Paris, France.
出版信息
Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4. doi: 10.1128/AAC.46.4.1122-1124.2002.
Abstract
We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy.
摘要
我们在耐甲氧西林金黄色葡萄球菌人工膝关节感染的兔模型中，比较了奎奴普丁-达福普汀（Q-D，每8小时30mg/kg体重）和万古霉素（每日两次，每次60mg/kg）单独使用或与利福平（每日两次，每次10mg/kg）联合使用的疗效。与万古霉素不同，与对照组相比，Q-D显著降低了每克骨组织中的平均log(10) 菌落形成单位数。利福平与Q-D或万古霉素联合使用均显著比单一疗法更有效。
相似文献
1
Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4. doi: 10.1128/AAC.46.4.1122-1124.2002.
2
Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93. doi: 10.1128/AAC.00675-11. Epub 2011 Aug 8.
3
Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Antimicrob Agents Chemother. 2001 Apr;45(4):1244-8. doi: 10.1128/AAC.45.4.1244-1248.2001.
4
Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model.
Int J Antimicrob Agents. 2008 Feb;31(2):158-60. doi: 10.1016/j.ijantimicag.2007.09.004. Epub 2007 Nov 19.
5
Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.
Antimicrob Agents Chemother. 2002 Jul;46(7):2174-8. doi: 10.1128/AAC.46.7.2174-2178.2002.
6
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.
J Antimicrob Chemother. 2000 Nov;46(5):775-84. doi: 10.1093/jac/46.5.775.
7
Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases.
Scand J Infect Dis. 2002;34(2):122-6. doi: 10.1080/00365540110077245.
8
Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci.
Intensive Care Med. 2002 Aug;28(8):1157-60. doi: 10.1007/s00134-002-1358-7. Epub 2002 Jun 20.
9
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):753-62. doi: 10.1164/ajrccm.161.3.9904115.
10
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 1990 Dec;34(12):2312-7. doi: 10.1128/AAC.34.12.2312.
引用本文的文献
1
Prosthetic Joint Infection Research Models in NZW Rabbits: Opportunities for Standardization-A Systematic Review.
J Funct Biomater. 2024 Oct 15;15(10):307. doi: 10.3390/jfb15100307.
2
Animal experimental investigation on the efficacy of antibiotic therapy with linezolid, vancomycin, cotrimoxazole, and rifampin in treatment of periprosthetic knee joint infections by MRSA.
Bone Joint Res. 2022 Mar;11(3):143-151. doi: 10.1302/2046-3758.113.BJR-2021-0268.R1.
3
A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model.
Front Immunol. 2021 Jul 2;12:676534. doi: 10.3389/fimmu.2021.676534. eCollection 2021.
4
Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.
PLoS One. 2020 Mar 19;15(3):e0230383. doi: 10.1371/journal.pone.0230383. eCollection 2020.
5
Emergency 1-stage anterior approach for cervical spine infection complicated by epidural abscess.
Medicine (Baltimore). 2017 Jun;96(26):e7301. doi: 10.1097/MD.0000000000007301.
6
Ceftaroline-Fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model.
Antimicrob Agents Chemother. 2014 Nov;58(11):6496-500. doi: 10.1128/AAC.03600-14. Epub 2014 Aug 18.
7
Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.
Antimicrob Agents Chemother. 2012 Dec;56(12):6291-7. doi: 10.1128/AAC.00926-12. Epub 2012 Oct 1.
8
Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93. doi: 10.1128/AAC.00675-11. Epub 2011 Aug 8.
9
Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections?
Curr Opin Microbiol. 2010 Oct;13(5):610-5. doi: 10.1016/j.mib.2010.09.007. Epub 2010 Sep 29.
10
Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm.
J Antimicrob Chemother. 2010 Oct;65(10):2164-71. doi: 10.1093/jac/dkq314. Epub 2010 Aug 18.
本文引用的文献
1
Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Antimicrob Agents Chemother. 2001 Apr;45(4):1244-8. doi: 10.1128/AAC.45.4.1244-1248.2001.
2
Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin.
Clin Infect Dis. 2000 Sep;31(3):684-9. doi: 10.1086/314035. Epub 2000 Oct 4.
3
The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria.
J Antimicrob Chemother. 2000 Jul;46(1):61-7. doi: 10.1093/jac/46.1.61.
4
Wound infection in hip and knee arthroplasty.
J Bone Joint Surg Br. 2000 May;82(4):561-5. doi: 10.1302/0301-620x.82b4.10305.
5
Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998.
Clin Infect Dis. 2000 Mar;30(3):454-60. doi: 10.1086/313710.
6
Chemotherapy for gram-positive nosocomial sepsis.
J Chemother. 1999 Dec;11(6):446-52. doi: 10.1179/joc.1999.11.6.446.
7
The threat of vancomycin resistance.
Am J Med. 1999 May 3;106(5A):26S-37S; discussion 48S-52S. doi: 10.1016/s0002-9343(98)00354-4.
8
Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
N Engl J Med. 1999 Feb 18;340(7):493-501. doi: 10.1056/NEJM199902183400701.
9
Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.
Antimicrob Agents Chemother. 1998 Nov;42(11):2830-5. doi: 10.1128/AAC.42.11.2830.
10
Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 1998 Oct;42(10):2590-4. doi: 10.1128/AAC.42.10.2590.
Zotero 插件